A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) with a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

Trial Identifier: D5985C00008
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: April 2024
Primary Completion Date: June 2024
Study Completion Date: June 2024
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation

Trial Locations

Country Location
DE Berlin, DE, 14050